The first causal therapy for atopic dermatitis (Neurodermitis), 6% prevalence. Medically superior over all alternatives, therapy result remains stable. Inexpensive treatment with high social impact.
2000 patients have been treated so far with the legacy devices. All of the dermatologists who were operating the devices are supporting the innovation. We are developing a new generation of devices actually, and we need a large study to enable insurance refunding of treatment costs.
Problem or Opportunity
Atopic dermatitis (Neurodermitis) cannot be cured with pharmaceuticals. Patients need medication for their remaining lifetime. If they stop medication, there will be a relapse. Newest pharmaceuticals are very expensive which is a burden for public health systems. There is little long-time experience with such pharmaceuticals. Another option is UV irradiation, having carcinogenic side effects and should not be used for children. Children and teenagers often suffer from atopic dermatitis.
Solution (product or service)
Blue Light irradiation, free of UV, is a new discovery to have an anti-inflammatory effect. Irradiation with DermoTech devices is the first causal therapy and patients do not need further treatment once therapy is achieved.
Research & development and manufacturing of blue light irradiation devices for therapy of human diseases caused by the immune system, bacteria, fungi or viruses.